Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
DETAILED ACTION
This office action is a response to Applicant’s amendments/remarks after non-final rejection filed 4/17/2026.
As filed, claims 1, 3-5 and 10 are pending; claims 6-9 and 11-15 are withdrawn; and claim 2 is cancelled.
Response to Amendments/Remarks
Applicant’s amendments/remarks, filed 4/17/2026, with respect to claims 1-5 and 10, have been fully considered and are entered. The status for each rejection in the previous Office Action is set out below.
The § 112(b) indefinite rejection of claims 1, 3, and 5 is withdrawn per amendments.
The § 102(a)(1) rejection of claims 1-5 and 10 by CAS397 is withdrawn per amendments and cancellation of claim 2.
The § 102(a)(1) rejection of claims 1 and 3 by SID177 is withdrawn per amendments.
The claim objection of claims 1, 3-5, and 10 is withdrawn per amendments.
Claim Rejections - 35 USC § 102
The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention.
Claims 1, 3, and 5 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Chemical Abstract Registry No. 443893-94-5, hereinafter CAS945.
Regarding claims 1, 3, and 5, CAS945 teaches the following compound or pharmaceutical composition thereof (with unbuffered water), which meets all the limitation of these claims.
PNG
media_image1.png
178
426
media_image1.png
Greyscale
PNG
media_image2.png
40
640
media_image2.png
Greyscale
Wherein: instant variable Ar1 is v)
PNG
media_image3.png
114
214
media_image3.png
Greyscale
; instant variables Y5-Y8 are C; instant variable L is -CONH-; instant variable Ar2 is phenyl substituted by -SO2-R10; and instant variable R10 is CF3-substituted phenylamino.
Claims 1, 3, 5, and 10 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Chemical Abstract Registry No. 604756-11-8, hereinafter CAS118.
Regarding claims 1 ,3 ,5 and 10, CAS118 teaches the following compound or pharmaceutical composition thereof (with unbuffered water), which meets all the limitation of these claims.
PNG
media_image4.png
128
342
media_image4.png
Greyscale
PNG
media_image5.png
38
646
media_image5.png
Greyscale
Wherein: instant variable Ar1 is i)
PNG
media_image6.png
170
236
media_image6.png
Greyscale
; instant variables X1 is O; instant variable R3 is H; instant variables R1 and R2 are methyl; instant variable L is -CONH-; instant variable Ar2 is phenyl substituted by -OR11; and instant variable R11 is methyl.
Allowable Subject Matter
Claim 4 is allowed.
Conclusion
Claims 1, 3, 5, and 10 are rejected.
Claim 4 is allowed.
Claims 6-9 and 11-15 are withdrawn.
Claim 2 is cancelled.
Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).
A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.
Telephone Inquiry
Any inquiry concerning this communication or earlier communications from the examiner should be directed to PO-CHIH CHEN whose telephone number is (571)270-7243. The examiner can normally be reached Monday - Friday 10:00 am to 6:00 pm.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Clinton Brooks can be reached at (571)270-7682. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/PO-CHIH CHEN/Primary Examiner, Art Unit 1621
Prosecution Insights